Display options
Cite
Kojima S, Cuttler JM, Inoguchi K, et al. Radon Therapy Is Very Promising as a Primary or an Adjuvant Treatment for Different Types of Cancers: 4 Case Reports. Dose Response. 2019;17(2):1559325819853163doi: 10.1177/1559325819853163.
Kojima, S., Cuttler, J. M., Inoguchi, K., Yorozu, K., Horii, T., Shimura, N., Koga, H., & Murata, A. (2019). Radon Therapy Is Very Promising as a Primary or an Adjuvant Treatment for Different Types of Cancers: 4 Case Reports. Dose-response : a publication of International Hormesis Society, 17(2), 1559325819853163. https://doi.org/10.1177/1559325819853163
Kojima, Shuji, et al. "Radon Therapy Is Very Promising as a Primary or an Adjuvant Treatment for Different Types of Cancers: 4 Case Reports." Dose-response : a publication of International Hormesis Society vol. 17,2 (2019): 1559325819853163. doi: https://doi.org/10.1177/1559325819853163
Kojima S, Cuttler JM, Inoguchi K, Yorozu K, Horii T, Shimura N, Koga H, Murata A. Radon Therapy Is Very Promising as a Primary or an Adjuvant Treatment for Different Types of Cancers: 4 Case Reports. Dose Response. 2019 Jun 03;17(2):1559325819853163. doi: 10.1177/1559325819853163. eCollection 2019. PMID: 31210758; PMCID: PMC6552369.
Copy Download .nbib Format: NLM
Share it on

Dose Response. 2019 Jun 03;17(2):1559325819853163. doi: 10.1177/1559325819853163. eCollection 2019.

Radon Therapy Is Very Promising as a Primary or an Adjuvant Treatment for Different Types of Cancers: 4 Case Reports.

Dose-response : a publication of International Hormesis Society

Shuji Kojima, Jerry M Cuttler, Kiyomi Inoguchi, Kenshou Yorozu, Takashisa Horii, Noriko Shimura, Hironobu Koga, Akihisa Murata

Affiliations

  1. Department of Radiation Biosciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS), Noda-city, Chiba, Japan.
  2. Cuttler and Associates Inc, Vaughan, Ontario, Canada.
  3. Drainage Co., Ltd, Minoo-city, Osaka, Japan.
  4. Yorozu Clinic, Totori-city, Japan.
  5. Horii Clinic, Nishinomiya-city, Japan.
  6. Faculty of Pharmaceutical Sciences, Ohu University, Koriyama, Japan.
  7. Lead and Company Co., Ltd., Minami-ku, Yokohama, Japan.

PMID: 31210758 PMCID: PMC6552369 DOI: 10.1177/1559325819853163

Abstract

We report on the application of radon inhalation therapy to patients with 4 types of cancer: colon, uterine, lung, and liver cell. The radon treatments were given to improve the efficacy of chemotherapy and were potent in all 4 cases. Marker values decreased and disease symptoms were alleviated. We include a lengthy discussion on the mechanism that may be responsible for the observed results. While employing the radon generator to treat the patient with hepatocellular carcinoma, we discovered that a concentration of 6 MBq/m

Keywords: breast cancer; colon uterine lung liver cancer; optimum radon concentration; primary or adjuvant treatment; radiation hormesis; radon therapy

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declare that there are no potential conflicts of interests with respect to the report, the authorship, and/or the publication of this article.

References

  1. Int J Radiat Biol. 1992 Aug;62(2):187-90 - PubMed
  2. J Radiat Res. 2003 Jun;44(2):95-9 - PubMed
  3. J Environ Radioact. 2004;74(1-3):107-16 - PubMed
  4. J Radiat Res. 2004 Mar;45(1):33-9 - PubMed
  5. J Radiat Res. 2004 Mar;45(1):83-8 - PubMed
  6. Jpn J Cancer Res. 1992 Jan;83(1):1-5 - PubMed
  7. Radiat Res. 2005 Feb;163(2):153-8 - PubMed
  8. Int J Radiat Biol. 2005 Oct;81(10):731-40 - PubMed
  9. Radiat Res. 2006 Mar;165(3):337-42 - PubMed
  10. Acta Oncol. 2006;45(4):493-7 - PubMed
  11. BMJ. 1992 Jan 25;304(6821):220-5 - PubMed
  12. Cell Immunol. 2006 Nov;244(1):50-6 - PubMed
  13. Radiat Res. 2008 Jan;169(1):59-66 - PubMed
  14. J Radiat Res. 2008 Jul;49(4):381-9 - PubMed
  15. Dose Response. 2006 Nov 27;5(1):26-38 - PubMed
  16. Dose Response. 2006 Aug 28;5(1):39-47 - PubMed
  17. Radiat Res. 2008 Oct;170(4):429-36 - PubMed
  18. Nonlinearity Biol Toxicol Med. 2003 Jan;1(1):71-92 - PubMed
  19. Nonlinearity Biol Toxicol Med. 2004 Oct;2(4):293-316 - PubMed
  20. Biochim Biophys Acta. 2010 Jan;1800(1):40-6 - PubMed
  21. Cell Mol Immunol. 2010 Mar;7(2):157-62 - PubMed
  22. J Radiat Res. 2010;51(3):349-53 - PubMed
  23. Dose Response. 2009 Dec 10;8(2):227-52 - PubMed
  24. Radiat Res. 2010 Sep;174(3):313-24 - PubMed
  25. Radiat Res. 2011 Feb;175(2):193-200 - PubMed
  26. J Radiat Res. 1990 Mar;31(1):119-36 - PubMed
  27. Expert Rev Anticancer Ther. 2011 May;11(5):791-802 - PubMed
  28. Dose Response. 2012 Dec;10(4):541-61 - PubMed
  29. J Radiat Res. 2013 Jul 1;54(4):587-96 - PubMed
  30. Dose Response. 2016 Nov 30;14(4):1559325816680539 - PubMed
  31. N Engl J Med. 1989 Nov 9;321(19):1285-9 - PubMed
  32. Cancer Immunol Immunother. 2017 Jul;66(7):819-832 - PubMed
  33. Cardiovasc Res. 2017 Jun 1;113(7):783-794 - PubMed
  34. Dose Response. 2017 Mar 23;15(1):1559325817697531 - PubMed
  35. Dose Response. 2018 Jan 22;16(1):1559325817747387 - PubMed
  36. Oncotarget. 2017 Dec 7;9(1):332-345 - PubMed
  37. Health Phys. 2018 Jun;114(6):623-626 - PubMed
  38. Dose Response. 2018 Jun 18;16(2):1559325818777326 - PubMed
  39. Dose Response. 2018 Jul 08;16(3):1559325818784719 - PubMed
  40. Dose Response. 2018 Nov 20;16(4):1559325818811537 - PubMed
  41. Dose Response. 2018 Dec 26;16(4):1559325818820211 - PubMed
  42. Dose Response. 2019 Jan 06;17(1):1559325818820973 - PubMed
  43. Hum Exp Toxicol. 2019 May 6;:960327119846925 - PubMed
  44. Health Phys. 1987 May;52(5):653-7 - PubMed
  45. Br J Radiol. 1983 Jan;56(661):63-6 - PubMed
  46. Radiother Oncol. 1993 Feb;26(2):177-9 - PubMed

Publication Types